NPI: 1437122009 · RAPID CITY, SD 57701 · Primary Care Clinic/Center · NPI assigned 02/13/2006
Authorized official PIERCE, JOHN controls 18+ related entities in our dataset. Read more
| Authorized Official | PIERCE, JOHN (MONUMENT HEALTH PRESIDENT) |
| NPI Enumeration Date | 02/13/2006 |
Other providers sharing the same authorized official: PIERCE, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 37,033 | $1.02M |
| 2019 | 39,981 | $1.37M |
| 2020 | 18,160 | $833K |
| 2021 | 42,337 | $2.01M |
| 2022 | 47,119 | $1.96M |
| 2023 | 47,364 | $1.80M |
| 2024 | 42,144 | $2.54M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 16,718 | 15,269 | $4.38M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 20,406 | 17,376 | $1.40M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 19,453 | 15,085 | $618K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,668 | 1,505 | $557K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 2,020 | 1,786 | $497K |
| G0378 | Hospital observation service, per hour | 43,092 | 937 | $474K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 20,477 | 7,807 | $427K |
| 96361 | Intravenous infusion, hydration; each additional hour | 828 | 771 | $411K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 34,319 | 3,634 | $410K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4,465 | 4,128 | $391K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1,004 | 910 | $375K |
| A9270 | Non-covered item or service | 36,347 | 9,433 | $322K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2,879 | 2,755 | $270K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 6,277 | 2,087 | $232K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 257 | 251 | $127K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 501 | 362 | $70K |
| 41899 | Unlisted procedure, dentoalveolar structures | 204 | 197 | $56K |
| J3490 | Unclassified drugs | 340 | 165 | $47K |
| 81001 | 3,271 | 2,994 | $46K | |
| 71046 | Radiologic examination, chest; 2 views | 374 | 332 | $40K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 196 | 196 | $39K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 2,008 | 787 | $36K |
| 71045 | Radiologic examination, chest; single view | 785 | 752 | $32K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 116 | 112 | $29K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 4,257 | 2,288 | $21K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 1,564 | 650 | $20K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 2,100 | 1,112 | $18K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 108 | 105 | $18K |
| 80053 | Comprehensive metabolic panel | 9,302 | 8,653 | $18K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 243 | 235 | $16K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1,526 | 327 | $15K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 585 | 512 | $12K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 33 | 32 | $10K |
| 87070 | 471 | 464 | $9K | |
| 70450 | Computed tomography, head or brain; without contrast material | 58 | 57 | $8K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 73 | 73 | $8K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 570 | 191 | $8K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4,850 | 4,495 | $7K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 1,258 | 411 | $6K |
| 87486 | 161 | 161 | $6K | |
| 87634 | 15 | 15 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 2,090 | 1,404 | $5K |
| J2704 | Injection, propofol, 10 mg | 3,442 | 1,793 | $5K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 11,755 | 10,862 | $5K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 614 | 320 | $4K |
| 93971 | 111 | 12 | $3K | |
| 97597 | 108 | 26 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 440 | 126 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 170 | 163 | $2K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 16 | 15 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 28 | 12 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 24 | 12 | $1K |
| 80306 | 42 | 40 | $1K | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 12 | 12 | $1K |
| Q3014 | Telehealth originating site facility fee | 221 | 168 | $1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 80 | 77 | $999.61 |
| 84443 | Thyroid stimulating hormone (TSH) | 98 | 94 | $928.98 |
| 80048 | Basic metabolic panel (calcium, ionized) | 277 | 264 | $828.58 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 662 | 507 | $681.11 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 25 | 24 | $633.04 |
| 83690 | 833 | 745 | $421.98 | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1,213 | 1,120 | $362.85 |
| J1170 | Injection, hydromorphone, up to 4 mg | 42 | 29 | $212.63 |
| 82077 | 431 | 397 | $162.94 | |
| 86140 | 29 | 25 | $97.64 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 37 | 25 | $79.50 |
| 83735 | 439 | 386 | $34.63 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 322 | 161 | $31.46 |
| 87581 | 161 | 161 | $31.46 | |
| 87088 | 16 | 13 | $28.93 | |
| 85652 | 32 | 28 | $19.38 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 168 | 168 | $0.01 |
| 85610 | 52 | 51 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 206 | 113 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 65 | 65 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 845 | 183 | $0.00 |
| 80143 | 182 | 176 | $0.00 | |
| 80179 | 180 | 174 | $0.00 | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 28 | 27 | $0.00 |
| 84439 | 41 | 40 | $0.00 | |
| 84703 | 393 | 370 | $0.00 | |
| 85027 | 627 | 593 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2,194 | 2,099 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 96 | 75 | $0.00 |
| 36410 | 15 | 14 | $0.00 | |
| 85730 | 51 | 50 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 24 | 24 | $0.00 |
| 84484 | 22 | 13 | $0.00 |